WO1992022283A1 - A process for producing suppositories by compression and suppositories obtained by the process - Google Patents

A process for producing suppositories by compression and suppositories obtained by the process Download PDF

Info

Publication number
WO1992022283A1
WO1992022283A1 PCT/DK1992/000187 DK9200187W WO9222283A1 WO 1992022283 A1 WO1992022283 A1 WO 1992022283A1 DK 9200187 W DK9200187 W DK 9200187W WO 9222283 A1 WO9222283 A1 WO 9222283A1
Authority
WO
WIPO (PCT)
Prior art keywords
suppositories
polyethylene glycol
weight
active drug
macrogol
Prior art date
Application number
PCT/DK1992/000187
Other languages
English (en)
French (fr)
Inventor
Søren Halskov
Original Assignee
Farmaceutisk Laboratorium Ferring A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmaceutisk Laboratorium Ferring A/S filed Critical Farmaceutisk Laboratorium Ferring A/S
Priority to DE69222323T priority Critical patent/DE69222323T2/de
Priority to AU19852/92A priority patent/AU659846B2/en
Priority to EP92912048A priority patent/EP0660704B1/en
Priority to CA002111697A priority patent/CA2111697C/en
Priority to JP50075093A priority patent/JP3286317B2/ja
Publication of WO1992022283A1 publication Critical patent/WO1992022283A1/en
Priority to FI935611A priority patent/FI105890B/fi
Priority to NO934647D priority patent/NO934647D0/no
Priority to NO934647A priority patent/NO306445B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules

Definitions

  • the present invention concerns a special process for pro- ducing suppositories by compression, and the process of the invention is characterized by producing a suppository mixture granulate containing a considerably greater amount of active drug than ordinary suppositories as well as 20- 50% by weight of a polyethylene glycol having an average molecular weight of at least 4000, and producing the sup ⁇ positories in the same manner as tablets, i.e. by compres ⁇ sion, instead of by moulding.
  • the invention moreover con ⁇ cerns the suppositories obtained by the process which have a considerably higher percentual content of active drug than ordinary suppositories.
  • suppositories are drugs intended for insertion into the rectum. They contain the active drug in a dosed amount and are produced by pressing, moulding or compression. They can also be produced in the form of cap ⁇ sules for controlled release of the active substance.
  • suppositories are produced by moulding, the produced mass being melted using the least possible amount of heat, and then the liquid mass is poured into moulds having the desired nominal capacity.
  • the suppositories produced by moulding are oblong and smooth, and they have a uniform appearance. Melting is in- tended to provide a uniform distribution of the drug in the basic mass, which, however, can be difficult to obtain because of sedimentation during hardening.
  • An object of the invention is to provide a process enab- ling the production of suppositories having a high content of active drug, which are partly more convenient to store and are partly more convenieny to use and easier and cheaper to produce than traditional melt-moulded supposi ⁇ tories.
  • the EP publication 111 137 describes suppositories containing the drug indomethacin in a base consisting of polyethylene glycol having an average molecular weight of up to 35,000. It is stated that the content of the active drug may be up to 50% by weight, but preferably the con ⁇ tent is 2-40% by weight and in particular 2-26% by weight. All the examples in the publication concern rectal tablets having a content of indomethacin of 2.8 - 5.8% by weight and rectal capsules having a content of indomethacin of 5.25 - 10.5% by weight, i.e. rather low concentrations.
  • the suppositories thus known contain quite high amounts of polyethylene glycols, typically 1600-1730 mg per unit, which is a drawback, because it has been found that a content of polyethylene glycols in suppositories of 1 - 1.5 g per unit may cause bowel disorders.
  • a composition which can easily be compressed to suppositories by an ordinary tabletting method can be obtained by using a suitable amount, more particularly 20-50% by weight of a polyethylene glycol having an average molecular weight of at least 4000 in the suppository basic mass.
  • a polyethylene glycol having an average molecular weight of at least 4000 in the suppository basic mass results in suppositories having a uniform appearance and having an extremely smooth and regular surface, which is moreover sufficiently slippery for the suppository to be inserted without difficulty. It is moreover possible in such suppo- sitories to incorporate up to 75% by weight of active drug, which is far above normal.
  • Macrogols Polyethylene glycols, more particularly mixtures of con ⁇ densation polymers of ethylene oxide and water, are also called “macrogols". Macrogols having average molecular weights of 200-700 are liquids, while macrogols having average molecular weights above 1000 vary in consistence from soft oily substances to hard wax-like solid sub ⁇ stances. The average molecular weight is stated as a number after the name. "Macrogol 6000”, which it is pre ⁇ ferred to use according to the invention, thus has an ave- rage molecular weight of about 6000.
  • the macrogols have the general formula
  • n is greater than or equal to 4.
  • n has an average value of between 158 and 204. It is a white or cream-coloured solid wax-like substance which is in the form of a powder or flakes.
  • the melting point is 56-63 ⁇ C, i.e. considerably above the body temperature. Mixtures of various polyethylene glycols having melting points above the body temperature have frequently been used as a base in suppositories from which the drug is released by dissolution.
  • macrogols having high average molecular weights have not previously been a natural choice as a suppository base material.
  • the drug can be incorporated in very high concentra ⁇ tions and is considerably easier to dose uniformly. 4) The product is more convenient and more pleasant to use for the patient.
  • 5-aminosalicylic acid 5-ASA
  • Suppositories containing 5- aminosalicylic acid are known e.g. from the EP patent application 83 775, these suppositories being produced by moulding and containing max. 500 mg of 5-aminosalicylic acid per dose unit.
  • the suppositories of the invention may contain considerably larger amounts of 5-ASA, which is absolutely an advantage for the patient.
  • steroids An example of the many active drugs which may be used is steroids for various applications.
  • the suppositories produced according to the invention contain microcrystalline cellulose and/or other additives common in the production of drugs. These additives and the active drug together amount to 45-75% based on the gross weight of the suppositories.
  • the suppositories contain one or more of the substances talc, magnesium stearate and polyvinyl pyrrolidone in an amount of 2-5% by weight.
  • the suppositories are typically compressed to symmetrical units having an approximately elliptic longitudinal sec ⁇ tion, i.e. the two ends are uniform (in contrast to the ordinary "torpedo-shape" where one end is pointed while the other is blunt).
  • a suppository basic mass for the production of 1000 suppo ⁇ sitories consists of the following ingredients:
  • Microgol 6000 572 g Microcrystalline cellulose and active drug 1000 g
  • a granulate is made from the microcrystalline cellulose, the active drug, e.g. 5-aminosalicylic acid (5-ASA) and the mixture of polyvinyl pyrrolidone and ethanol.
  • the active drug e.g. 5-aminosalicylic acid (5-ASA)
  • the mixture of polyvinyl pyrrolidone and ethanol e.g. 5-aminosalicylic acid (5-ASA)
  • the resulting granulate is mixed with "Macrogol 6000", and then magnesium stearate and talc are added.
  • the granulate can then be compressed to suppositories in a tabletting machine in a manner known per se.
PCT/DK1992/000187 1991-06-17 1992-06-16 A process for producing suppositories by compression and suppositories obtained by the process WO1992022283A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DE69222323T DE69222323T2 (de) 1991-06-17 1992-06-16 Verfahren zur herstellung von suppositorien durch kompression und durch dieses verfahren erhaltene suppositorien
AU19852/92A AU659846B2 (en) 1991-06-17 1992-06-16 A process for producing suppositories by compression and suppositories obtained by the process
EP92912048A EP0660704B1 (en) 1991-06-17 1992-06-16 A process for producing suppositories by compression and suppositories obtained by the process
CA002111697A CA2111697C (en) 1991-06-17 1992-06-16 A process for producing suppositories by compression and suppositories obtained by the process
JP50075093A JP3286317B2 (ja) 1991-06-17 1992-06-16 圧縮による座薬の製造方法およびその得られた座薬
FI935611A FI105890B (fi) 1991-06-17 1993-12-14 Menetelmä peräpuikkojen valmistamiseksi puristamalla
NO934647D NO934647D0 (no) 1991-06-17 1993-12-16 Fremgangsmaate for fremstilling av stikkpiller ved sammenpresning, og stikkpiller erholdt ved fremgangsmaaten
NO934647A NO306445B1 (no) 1991-06-17 1993-12-16 FremgangsmÕte for fremstilling av stikkpiller ved sammenpressing, og stikkpiller erholdt ved fremgangsmÕten

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK911165A DK116591D0 (da) 1991-06-17 1991-06-17 Fremgangsmaade til fremstilling af suppositorier ved komprimering og suppositorier opnaaet ved fremgangsmaaden
DK1165/91 1991-06-17

Publications (1)

Publication Number Publication Date
WO1992022283A1 true WO1992022283A1 (en) 1992-12-23

Family

ID=8101725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1992/000187 WO1992022283A1 (en) 1991-06-17 1992-06-16 A process for producing suppositories by compression and suppositories obtained by the process

Country Status (11)

Country Link
EP (1) EP0660704B1 (da)
JP (1) JP3286317B2 (da)
AT (1) ATE158173T1 (da)
AU (1) AU659846B2 (da)
CA (1) CA2111697C (da)
DE (1) DE69222323T2 (da)
DK (2) DK116591D0 (da)
ES (1) ES2108119T3 (da)
FI (1) FI105890B (da)
NO (2) NO306445B1 (da)
WO (1) WO1992022283A1 (da)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706281B2 (en) * 1994-11-04 2004-03-16 Euro-Celtique, S.A. Melt-extrusion multiparticulates

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248777A1 (de) * 1971-10-06 1973-04-19 Merck & Co Inc Indometacin-suppositorium
EP0111137A2 (de) * 1982-11-09 1984-06-20 Troponwerke GmbH & Co. KG Indometacin enthaltende rektale Zubereitungen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4999342A (en) * 1988-08-16 1991-03-12 Ortho Pharmaceutical Corporation Long lasting contraceptive suppository composition and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248777A1 (de) * 1971-10-06 1973-04-19 Merck & Co Inc Indometacin-suppositorium
EP0111137A2 (de) * 1982-11-09 1984-06-20 Troponwerke GmbH & Co. KG Indometacin enthaltende rektale Zubereitungen

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706281B2 (en) * 1994-11-04 2004-03-16 Euro-Celtique, S.A. Melt-extrusion multiparticulates

Also Published As

Publication number Publication date
NO306445B1 (no) 1999-11-08
NO934647D0 (no) 1993-12-16
ES2108119T3 (es) 1997-12-16
CA2111697A1 (en) 1992-12-23
ATE158173T1 (de) 1997-10-15
AU1985292A (en) 1993-01-12
DE69222323T2 (de) 1998-03-12
DK0660704T3 (da) 1997-10-13
FI935611A0 (fi) 1993-12-14
DK116591D0 (da) 1991-06-17
FI935611A (fi) 1993-12-14
JP3286317B2 (ja) 2002-05-27
EP0660704B1 (en) 1997-09-17
CA2111697C (en) 2002-08-20
AU659846B2 (en) 1995-06-01
EP0660704A1 (en) 1995-07-05
NO934647L (no) 1993-12-16
JPH06508361A (ja) 1994-09-22
DE69222323D1 (de) 1997-10-23
FI105890B (fi) 2000-10-31

Similar Documents

Publication Publication Date Title
US3147187A (en) Sustained release pharmaceutical
KR100413581B1 (ko) 용융성(fusible)담체를함유하는약제학적조성물및그제조방법
CN1022666C (zh) 固体药物剂型的制备
JP2793280B2 (ja) モルヒネ含有組成物
US4814179A (en) Floating sustained release therapeutic compositions
RU2101009C1 (ru) Твердая лекарственная форма для орального применения с замедленным высвобождением активного вещества и способ ее изготовления (варианты)
WO1994025008A1 (en) Pharmaceutical compositions containing polyvinylpyrrolidone and a tri-ester and process of manufacture thereof
IL145783A (en) Process and method for preparing a pharmaceutical composition in dosage forms that dissipate rapidly using fish gelatin
JPH09508128A (ja) 難溶性医薬活性剤の溶解方法
US5629012A (en) Process for producing suppositories by compression and suppositories obtained by the process
US3590117A (en) Long-lasting troche containing guar gum
US3976601A (en) Water soluble lubricant for tabletting compositions
CA1203480A (en) Compressed products with retarded release of active substance
WO1992022283A1 (en) A process for producing suppositories by compression and suppositories obtained by the process
US3594467A (en) Long-lasting troche
UA27954C2 (uk) Біологічно активна речовина фармацевтичної композиції для лікування гіперглікемій та фармацевтична композиція з протигіперглікемічною активністю
JP3904617B2 (ja) 緩下剤組成物の製造方法
KR950007203B1 (ko) 지효성 거환(巨丸) 배합물의 제조방법
US3920806A (en) Growth promoting subcutaneous compositions
US3358687A (en) Suppositories
JPS59101420A (ja) インドメタシンを含有する直腸用調製物
JPS5744634A (en) Preparation of lamellar polystyrene resin foam
JPH05507651A (ja) 放出可能な状態で結合された活性物質
JPH0640889A (ja) 座薬製剤
RU2114610C1 (ru) Суппозитории вагинальные для лечения трихомонадного и неспецифического кольпитов

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1992912048

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 935611

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 2111697

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 1993 167818

Country of ref document: US

Date of ref document: 19931217

Kind code of ref document: A

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1992912048

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1992912048

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 935611

Country of ref document: FI